Lipocine, Inc. (LPCN)
1.615
+0.08
(+5.56%)
USD |
NASDAQ |
Nov 06, 10:24
Lipocine Enterprise Value : -10.65M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -10.65M |
| November 04, 2026 | -11.39M |
| November 03, 2026 | -11.23M |
| November 02, 2026 | -11.31M |
| October 30, 2026 | -11.39M |
| October 29, 2026 | -10.74M |
| October 28, 2026 | -10.82M |
| October 27, 2026 | -11.23M |
| October 26, 2026 | -11.31M |
| October 23, 2026 | -11.39M |
| October 22, 2026 | -11.23M |
| October 21, 2026 | -10.08M |
| October 20, 2026 | -9.911M |
| October 19, 2026 | -10.65M |
| October 16, 2026 | -10.41M |
| October 15, 2026 | -9.416M |
| October 14, 2026 | -9.334M |
| October 13, 2026 | -9.911M |
| October 12, 2026 | -9.581M |
| October 09, 2026 | -9.086M |
| October 08, 2026 | -7.355M |
| October 07, 2026 | -5.129M |
| October 06, 2026 | -5.954M |
| October 05, 2026 | -6.201M |
| October 02, 2026 | -6.366M |
| Date | Value |
|---|---|
| October 01, 2026 | -6.201M |
| September 30, 2026 | -5.129M |
| September 29, 2026 | -5.459M |
| September 28, 2026 | -6.036M |
| September 25, 2026 | -5.954M |
| September 24, 2026 | -6.036M |
| September 23, 2026 | -5.789M |
| September 22, 2026 | -5.459M |
| September 21, 2026 | -4.799M |
| September 18, 2026 | -5.047M |
| September 17, 2026 | -4.964M |
| September 16, 2026 | -5.459M |
| September 15, 2026 | -5.253M |
| September 14, 2026 | -4.964M |
| September 11, 2026 | -4.552M |
| September 10, 2026 | -4.717M |
| September 09, 2026 | -4.717M |
| September 08, 2026 | -3.810M |
| September 04, 2026 | -3.068M |
| September 03, 2026 | -3.315M |
| September 02, 2026 | -3.851M |
| September 01, 2026 | -4.305M |
| August 31, 2026 | -4.799M |
| August 28, 2026 | -5.376M |
| August 27, 2026 | -4.882M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 682.93B |
| ANI Pharmaceuticals, Inc. | 1.834B |
| Corcept Therapeutics, Inc. | 7.472B |
| Veru, Inc. | 12.02M |
| Eli Lilly & Co. | 1.329T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.623M |
| Revenue (Quarterly) | 0.1901M |
| Total Expenses (Quarterly) | 2.813M |
| EPS Diluted (Quarterly) | -0.3192 |
| Gross Profit Margin (Quarterly) | 92.32% |
| Profit Margin (Quarterly) | -1.38K% |
| Earnings Yield | -115.4% |
| Normalized Earnings Yield | -115.42 |